Literature DB >> 9515834

Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego.

E G Eakin1, P M Resnikoff, L M Prewitt, A L Ries, R M Kaplan.   

Abstract

OBJECTIVE: Evaluate the reliability and validity of a new version of the University of California, San Diego Shortness of Breath Questionnaire (SOBQ), a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living.
DESIGN: PATIENTS enrolled in a pulmonary rehabilitation program were asked to complete the SOBQ, the Quality of Well-Being Scale, the Center for Epidemiologic Studies Depression Scale, and a 6-min walk with modified Borg scale ratings of perceived breathlessness following the walk.
SETTING: University medical center pulmonary rehabilitation program. PATIENTS: Thirty-two male subjects and 22 female subjects with a variety of pulmonary diagnoses: COPD (n=28), cystic fibrosis (n=9), and postlung transplant (n=17). MEASUREMENTS AND
RESULTS: The current version of the SOBQ was compared with the previous version, the format of which often resulted in a significant number of "not applicable" answers. The results demonstrated that the SOBQ had excellent internal consistency (alpha=0.96). The SOBQ was also significantly correlated with all validity criteria.
CONCLUSIONS: The SOBQ is a valuable assessment tool in both clinical practice and research in patients with moderate-to-severe lung disease.

Entities:  

Mesh:

Year:  1998        PMID: 9515834     DOI: 10.1378/chest.113.3.619

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  120 in total

Review 1.  The prediction of benefit from pulmonary rehabilitation: setting, training intensity and the effect of selection by disability.

Authors:  M D Morgan
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer.

Authors:  Gregory M M Videtic; Chandana A Reddy; Lisa Sorenson
Journal:  Support Care Cancer       Date:  2012-06-02       Impact factor: 3.603

3.  High Prevalence of Obstructive Sleep Apnea in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.

Authors:  Xavier Soler; Eduardo Gaio; Frank L Powell; Joe W Ramsdell; Jose S Loredo; Atul Malhotra; Andrew L Ries
Journal:  Ann Am Thorac Soc       Date:  2015-08

4.  Quality of life and healthcare use in a randomized controlled lung cancer screening study.

Authors:  Peter J Mazzone; Nancy Obuchowski; Alex Z Fu; Michael Phillips; Moulay Meziane
Journal:  Ann Am Thorac Soc       Date:  2013-08

5.  Effect of symptoms on physical performance in COPD.

Authors:  Jungeun Lee; Huong Q Nguyen; Monica E Jarrett; Pamela H Mitchell; Kenneth C Pike; Vincent S Fan
Journal:  Heart Lung       Date:  2018-02-01       Impact factor: 2.210

6.  Associations between symptoms, functioning, and perceptions of mastery with global self-rated health in patients with COPD: a cross-sectional study.

Authors:  Huong Q Nguyen; DorAnne Donesky-Cuenco; Virginia Carrieri-Kohlman
Journal:  Int J Nurs Stud       Date:  2007-11-05       Impact factor: 5.837

Review 7.  Natural history of emphysema.

Authors:  Omar A Minai; Joshua Benditt; Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 8.  The evaluation and preparation of the patient for lung volume reduction surgery.

Authors:  Malcolm M DeCamp; David Lipson; Mark Krasna; Omar A Minai; Robert J McKenna; Byron M Thomashow
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 9.  Health-related quality of life in emphysema.

Authors:  Robert M Kaplan; Andrew L Ries
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  Symptom cluster, healthcare use and mortality in patients with severe chronic obstructive pulmonary disease.

Authors:  Soo Kyung Park; Janet L Larson
Journal:  J Clin Nurs       Date:  2014-01-27       Impact factor: 3.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.